Analysts expect that OptimizeRx Co. (NASDAQ:OPRX) will announce $0.08 earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for OptimizeRx’s earnings. The lowest EPS estimate is $0.07 and the highest is $0.10. OptimizeRx posted earnings per share of $0.02 in the same quarter last year, which indicates a positive year-over-year growth rate of 300%. The company is scheduled to announce its next quarterly earnings report on Tuesday, August 6th.
According to Zacks, analysts expect that OptimizeRx will report full-year earnings of $0.41 per share for the current financial year, with EPS estimates ranging from $0.36 to $0.43. For the next financial year, analysts expect that the firm will report earnings of $0.65 per share, with EPS estimates ranging from $0.55 to $0.74. Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for OptimizeRx.
Separately, Zacks Investment Research cut shares of Hess Midstream Partners from a “hold” rating to a “sell” rating in a research note on Tuesday, May 14th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. OptimizeRx has an average rating of “Buy” and a consensus price target of $19.00.
In related news, major shareholder Awm Investment Company, Inc. sold 82,126 shares of the company’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $13.64, for a total transaction of $1,120,198.64. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Institutional investors have recently modified their holdings of the business. BlackRock Inc. acquired a new stake in OptimizeRx in the 4th quarter worth about $55,000. Northern Trust Corp increased its holdings in OptimizeRx by 71.5% during the 4th quarter. Northern Trust Corp now owns 17,474 shares of the company’s stock worth $192,000 after purchasing an additional 7,283 shares during the last quarter. Geode Capital Management LLC increased its holdings in OptimizeRx by 294.7% during the 4th quarter. Geode Capital Management LLC now owns 60,861 shares of the company’s stock worth $667,000 after purchasing an additional 45,440 shares during the last quarter. 1492 Capital Management LLC purchased a new stake in OptimizeRx during the 4th quarter worth approximately $1,454,000. Finally, Bank of America Corp DE increased its holdings in OptimizeRx by 15.8% during the 4th quarter. Bank of America Corp DE now owns 15,302 shares of the company’s stock worth $168,000 after purchasing an additional 2,084 shares during the last quarter. Institutional investors own 48.47% of the company’s stock.
OptimizeRx Company Profile
OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers. The company's cloud-based solutions support patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information; and network consists of electronic health records platforms, which provide the ambulatory patient market with access to their workflow at the point-of-care.
Featured Article: Current Ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.